-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 VnXp+INWhmzWCUPI6Gx5YpXCfXDZ1KGQQoERn4qUXXC5CShb8cB3rU3oYZRKNP9E
 jInCNuFXqcPTzNaOc9nKnw==

<SEC-DOCUMENT>0001460300-10-000002.txt : 20101217
<SEC-HEADER>0001460300-10-000002.hdr.sgml : 20101217
<ACCEPTANCE-DATETIME>20101216173827
ACCESSION NUMBER:		0001460300-10-000002
CONFORMED SUBMISSION TYPE:	D
PUBLIC DOCUMENT COUNT:		1
ITEM INFORMATION:		Rule 506
FILED AS OF DATE:		20101217
DATE AS OF CHANGE:		20101216
EFFECTIVENESS DATE:		20101217

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cahaba Pharmaceuticals, LLC
		CENTRAL INDEX KEY:			0001460300
		IRS NUMBER:				263991510
		STATE OF INCORPORATION:			DE

	FILING VALUES:
		FORM TYPE:		D
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	021-152053
		FILM NUMBER:		101257771

	BUSINESS ADDRESS:	
		BUSINESS PHONE:		205-263-2332

	MAIL ADDRESS:	
		STREET 1:		2501 20TH PLACE SOUTH
		STREET 2:		SUITE 275
		CITY:			BIRMINGHAM
		STATE:			AL
		ZIP:			25223-1702
</SEC-HEADER>
<DOCUMENT>
<TYPE>D
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<edgarSubmission>

    <schemaVersion>X0704</schemaVersion>

    <submissionType>D</submissionType>

    <testOrLive>LIVE</testOrLive>

    <primaryIssuer>
        <cik>0001460300</cik>
        <entityName>Cahaba Pharmaceuticals, LLC</entityName>
        <issuerAddress>
            <street1>103 Carnegie Center, Suite 300</street1>
            <city>Princeton</city>
            <stateOrCountry>NJ</stateOrCountry>
            <stateOrCountryDescription>NEW JERSEY</stateOrCountryDescription>
            <zipCode>08540</zipCode>
        </issuerAddress>
        <issuerPhoneNumber>609-524-2288</issuerPhoneNumber>
        <jurisdictionOfInc>DELAWARE</jurisdictionOfInc>
        <issuerPreviousNameList>
            <value>None</value>
        </issuerPreviousNameList>
        <edgarPreviousNameList>
            <value>None</value>
        </edgarPreviousNameList>
        <entityType>Limited Liability Company</entityType>
        <yearOfInc>
            <withinFiveYears>true</withinFiveYears>
            <value>2008</value>
        </yearOfInc>
    </primaryIssuer>

    <relatedPersonsList>
        <relatedPersonInfo>
            <relatedPersonName>
                <firstName>Andrew</firstName>
                <middleName>P.</middleName>
                <lastName>Aromando</lastName>
            </relatedPersonName>
            <relatedPersonAddress>
                <street1>103 Carnegie Center, Suite 300</street1>
                <city>Princeton</city>
                <stateOrCountry>NJ</stateOrCountry>
                <stateOrCountryDescription>NEW JERSEY</stateOrCountryDescription>
                <zipCode>08540</zipCode>
            </relatedPersonAddress>
            <relatedPersonRelationshipList>
                <relationship>Executive Officer</relationship>
            </relatedPersonRelationshipList>
            <relationshipClarification></relationshipClarification>
        </relatedPersonInfo>
        <relatedPersonInfo>
            <relatedPersonName>
                <firstName>William</firstName>
                <middleName>P.</middleName>
                <lastName>Testa</lastName>
            </relatedPersonName>
            <relatedPersonAddress>
                <street1>103 Carnegie Center, Suite 300</street1>
                <city>Princeton</city>
                <stateOrCountry>NJ</stateOrCountry>
                <stateOrCountryDescription>NEW JERSEY</stateOrCountryDescription>
                <zipCode>08540</zipCode>
            </relatedPersonAddress>
            <relatedPersonRelationshipList>
                <relationship>Executive Officer</relationship>
            </relatedPersonRelationshipList>
            <relationshipClarification></relationshipClarification>
        </relatedPersonInfo>
        <relatedPersonInfo>
            <relatedPersonName>
                <firstName>Madding</firstName>
                <lastName>King, III</lastName>
            </relatedPersonName>
            <relatedPersonAddress>
                <street1>2501 Twentieth Street Place S, STE 275</street1>
                <city>Birmingham</city>
                <stateOrCountry>AL</stateOrCountry>
                <stateOrCountryDescription>ALABAMA</stateOrCountryDescription>
                <zipCode>35223-1702</zipCode>
            </relatedPersonAddress>
            <relatedPersonRelationshipList>
                <relationship>Executive Officer</relationship>
                <relationship>Director</relationship>
            </relatedPersonRelationshipList>
            <relationshipClarification>Manages Brookline CPMM, LLC, which is Manager of Cahaba Pharmaceuticals, LLC</relationshipClarification>
        </relatedPersonInfo>
        <relatedPersonInfo>
            <relatedPersonName>
                <firstName>J.</firstName>
                <middleName>Rainer</middleName>
                <lastName>Twiford</lastName>
            </relatedPersonName>
            <relatedPersonAddress>
                <street1>2501 Twentieth Street Place S, STE 275</street1>
                <city>Birmingham</city>
                <stateOrCountry>AL</stateOrCountry>
                <stateOrCountryDescription>ALABAMA</stateOrCountryDescription>
                <zipCode>35223-1702</zipCode>
            </relatedPersonAddress>
            <relatedPersonRelationshipList>
                <relationship>Executive Officer</relationship>
                <relationship>Director</relationship>
            </relatedPersonRelationshipList>
            <relationshipClarification>Manages Brookline CPMM, LLC, which is Manager of Cahaba Pharmaceuticals, LLC</relationshipClarification>
        </relatedPersonInfo>
    </relatedPersonsList>

    <offeringData>
        <industryGroup>
            <industryGroupType>Pharmaceuticals</industryGroupType>
        </industryGroup>
        <issuerSize>
            <revenueRange>No Revenues</revenueRange>
        </issuerSize>
        <federalExemptionsExclusions>
            <item>06</item>
        </federalExemptionsExclusions>
        <typeOfFiling>
            <newOrAmendment>
                <isAmendment>false</isAmendment>
            </newOrAmendment>
            <dateOfFirstSale>
                <yetToOccur>true</yetToOccur>
            </dateOfFirstSale>
        </typeOfFiling>
        <durationOfOffering>
            <moreThanOneYear>false</moreThanOneYear>
        </durationOfOffering>
        <typesOfSecuritiesOffered>
            <isDebtType>true</isDebtType>
            <isOptionToAcquireType>true</isOptionToAcquireType>
            <isSecurityToBeAcquiredType>true</isSecurityToBeAcquiredType>
        </typesOfSecuritiesOffered>
        <businessCombinationTransaction>
            <isBusinessCombinationTransaction>false</isBusinessCombinationTransaction>
            <clarificationOfResponse></clarificationOfResponse>
        </businessCombinationTransaction>
        <minimumInvestmentAccepted>50000</minimumInvestmentAccepted>
        <salesCompensationList>
            <recipient>
                <recipientName>Michael A. Silverman</recipientName>
                <recipientCRDNumber>4351669</recipientCRDNumber>
                <associatedBDName>Gottbetter Capital Markets, LLC</associatedBDName>
                <associatedBDCRDNumber>20680</associatedBDCRDNumber>
                <recipientAddress>
                    <street1>488 Madison Avenue, 12th Floor</street1>
                    <city>New York</city>
                    <stateOrCountry>NY</stateOrCountry>
                    <stateOrCountryDescription>NEW YORK</stateOrCountryDescription>
                    <zipCode>10022</zipCode>
                </recipientAddress>
                <statesOfSolicitationList>
                    <state>AL</state>
                    <description>ALABAMA</description>
                    <state>CA</state>
                    <description>CALIFORNIA</description>
                    <state>PA</state>
                    <description>PENNSYLVANIA</description>
                </statesOfSolicitationList>
                <foreignSolicitation>false</foreignSolicitation>
            </recipient>
        </salesCompensationList>
        <offeringSalesAmounts>
            <totalOfferingAmount>3000000</totalOfferingAmount>
            <totalAmountSold>0</totalAmountSold>
            <totalRemaining>3000000</totalRemaining>
            <clarificationOfResponse></clarificationOfResponse>
        </offeringSalesAmounts>
        <investors>
            <hasNonAccreditedInvestors>false</hasNonAccreditedInvestors>
            <totalNumberAlreadyInvested>0</totalNumberAlreadyInvested>
        </investors>
        <salesCommissionsFindersFees>
            <salesCommissions>
                <dollarAmount>300000</dollarAmount>
                <isEstimate>true</isEstimate>
            </salesCommissions>
            <findersFees>
                <dollarAmount>0</dollarAmount>
            </findersFees>
            <clarificationOfResponse>Assumes a fully subscribed offering</clarificationOfResponse>
        </salesCommissionsFindersFees>
        <useOfProceeds>
            <grossProceedsUsed>
                <dollarAmount>264000</dollarAmount>
            </grossProceedsUsed>
            <clarificationOfResponse>$22,000.00 per month to Chief Executive Officer</clarificationOfResponse>
        </useOfProceeds>
        <signatureBlock>
            <authorizedRepresentative>false</authorizedRepresentative>
            <signature>
                <issuerName>Cahaba Pharmaceuticals, LLC</issuerName>
                <signatureName>Michel M. Marcoux</signatureName>
                <nameOfSigner>Michel M. Marcoux</nameOfSigner>
                <signatureTitle>Authorized Company Signatory by Power of Attorney</signatureTitle>
                <signatureDate>2010-12-16</signatureDate>
            </signature>
        </signatureBlock>
    </offeringData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----